Atacand Related Published Studies
Well-designed clinical trials related to Atacand (Candesartan Cilexetil)
Comparison of the efficacy and safety of azilsartan with that of candesartan
cilexetil in Japanese patients with grade I-II essential hypertension: a
randomized, double-blind clinical study. [2012]
Efficacy and safety of combination therapy with candesartan cilexetil and
pioglitazone hydrochloride in patients with hypertension and type 2 diabetes
mellitus. [2011]
Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. [2010.05]
Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. [2010.03]
Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. [2009.12]
Supramaximal dose of candesartan in proteinuric renal disease. [2009.04]
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. [2009]
Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: A randomized, double-blind, parallel-group study in primary care. [2009]
Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. [2008.12]
Comparison of the effects of candesartan cilexetil and enalapril maleate on right ventricular myocardial remodeling in dogs with experimentally induced pulmonary stenosis. [2008.12]
Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. [2008.10]
Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4-5 chronic kidney disease. [2008.08]
A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation. [2006.10]
Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension. [2006.09]
Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. [2006]
Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease. [2005.10]
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan. [2005.08]
Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. [2005.04]
Physicians' attitudes towards and reasons for participation in the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. [2005.03]
Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. [2005.02]
Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. [2005.02]
Efficacy and tolerability of candesartan cilexetil vs. amlodipine as assessed by home blood pressure in hypertensive patients. [2005.01]
The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance. [2005.01]
[Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals] [2005]
Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. [2004.10]
Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials. [2004.09]
Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension. [2004.01]
Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. [2003.10]
The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. [2003.07]
Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure. [2003.06]
Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure. [2003.03]
Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis. [2002.09]
Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients. [2001.10]
A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. [2001.07]
[Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)] [2001.05.11]
A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy. [2001.05]
Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. [2001.03.15]
Comparison of candesartan versus enalapril in essential hypertension. Italian Candesartan Study Group. [2001.02]
Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. [2001.01]
The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. [2001]
Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide. [2001]
Effects of candesartan cilexetil on health-related quality of life in black patients with systemic hypertension in the ABC Trial. [2000.11]
Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC Trial. [2000.11]
A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. [2000.11]
Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators. [2000.09]
Candesartan cilexetil and renal hemodynamics in hypertensive patients. [2000.09]
Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. [2000.05]
Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. [2000.04]
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. [2000.04]
Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Multicentre Cough Study Group. [2000.02]
Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension--comparison with a combination of losartan and hydrochlorothiazide. [2000]
A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators. [1999.12]
Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. [1999.11.30]
Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension. [1999.11.18]
Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. [1999.11.18]
Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. [1999.09]
Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. [1999.08.01]
Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group. [1999.05]
Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan. [1999.04]
Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study Investigators. [1999.03]
Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study Investigators. [1999.01.15]
Candesartan cilexetil in hypertension: effects of six weeks' treatment on haemodynamics, baroreceptor sensitivity and the renin-angiotensin-aldosterone system. [1999]
Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. [1998.10.15]
Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man. [1998.06]
Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes. [1998.05]
The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. [1998.01]
Effects of candesartan cilexetil on glucose homeostasis. Multicenter Study Group. [1998]
The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. [1997.09]
Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. [1997.09]
Pharmacokinetic drug interaction studies with candesartan cilexetil. [1997.09]
Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. [1997.09]
Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension--a population analysis. [1997]
Well-designed clinical trials possibly related to Atacand (Candesartan Cilexetil)
Reflex systemic sympatho-neural response to brachial adenosine infusion in treated heart failure. [2011.05]
Renin-angiotensin system blockade safely reduces blood pressure in patients with minor ischemic stroke during the acute phase. [2010.11]
Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis. [2008.02]
Treatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blocker. [2007.07]
Palatability of angiotensin II antagonists among nephropathic children. [2007.05]
Feasibility of treating prehypertension with an angiotensin-receptor blocker. [2006.04.20]
Effect of nos inhibition on retinal arterial and capillary circulation in early arterial hypertension. [2006.04]
Is low-risk hypertension fact or fiction? cardiovascular risk profile in the TROPHY study. [2005.07]
Effects of angiotensin type-1 receptor antagonism on small artery function in patients with type 2 diabetes mellitus. [2005.02]
Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment. [2004.12]
Impaired endothelial function of the retinal vasculature in hypertensive patients. [2004.06]
Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans. [2004.04]
Switch from ABCD pretreatment to A-II-A treatment: a multinational, open, centrally randomized, prospective parallel group comparison. [2004]
The effects of replacing dihydropyridine calcium-channel blockers with angiotensin II receptor blocker on the quality of life of hypertensive patients. [2003.12]
Cognitive associations of subcortical white matter lesions in older people. [2002.11]
Can hypertension be prevented? The Danish Hypertension Prevention Project and the Trial of Prevention of Hypertension studies. [2002.07]
Comparison of the effects of antihypertensive treatment with angiotensin II blockade and beta-blockade on carotid wall structure and haemodynamics: protocol and baseline demographics. [2002.06]
Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. [2002.01]
Acute precipitants of congestive heart failure exacerbations. [2001.10.22]
Discordant responses to two classes of drugs acting on the renin-angiotensin system. [2001.03]
The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man. [2000.12]
Psychometric properties of the VSQLQ in black patients with mild hypertension. Vital Signs Quality of Life Questionnaire. [2000.12]
Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. [2000.09]
Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. [2000.03.01]
Reducing cardiovascular morbidity and mortality in the elderly. [2000]
Study on COgnition and Prognosis in the Elderly (SCOPE): baseline characteristics. [2000]
Study on COgnition and Prognosis in the Elderly (SCOPE). [1999]
Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. [1995.01]
Effect of an angiotensin receptor antagonist, TCV-116, on sympathetic nerve activity in patients with essential hypertension. [1994]
|
